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PRADl (Cyclin Dl): A Parathyroid Neoplasia Gene on llql3 
Andrew Arnold,* Torn Motokura,* Theodora Bloom,^  Carol Rosenberg,* Allen Bale,* 
Henry Kronenberg,* Joan Ruderman,^  Milton Brown,* and Hyung Goo Kim* 
Hyperparathyroidism is a central component of multiple endocrine neoplasia type I (MEN 1), and 
both sporadic and familial forms of parathyroid disease may share certain pathogenetic features. We 
recently identified a gene that is clonally rearranged with the PTH locus in a subset of sporadic 
parathyroid adenomas. This candidate oncogene, PRADl (previously Dl 1S287), appears to contrib-
ute to parathyroid tumorigenesis in a fashion analogous to activation of C-MYC or BCL-2 by 
rearrangement with tissue-specific enhancers ofthe immunoglobulin genes in B-lymphoid neoplasia. 
The PRADl gene maps to I lqI3 and has been linked to the BCL-l breakpoint locus, although not to 
the most tightly linked MEN I markers, by pulsed field gel electrophoresis. PRADl may. in fact, be the 
long-sought BCL-l lymphoma oncogene. PRADl encodes a novel type of cyclin protein and thus may 
normally function in controlling the cell cycle, perhaps through direct interaction with cdc2 or a 
related kinase. PRADl s possible primary, or more likely secondary, involvement in the pathogenesis 
of MEN 1-related tumors is unknown and under investigation. (Henry Ford Hosp Med J 1992:40:177-
80) 
Hyperparathyroidism is a central component of familial multiple endocrine neoplasia type 1 (MEN 1), Our recent 
identification of a cellular oncogene that appears to participate 
in the pathogenesis of a subset of nonfamilial or sporadic para-
thyroid adenomas could be relevant in MEN 1, since familial 
and sporadic forms of other types of tumors can share pathoge-
netic features. We provide a brief review of the characterization 
ofthis gene. PRADl (or cyclin Dl) . 
During studies that established the monoclonality of parathy-
roid adenomas, we encountered two tumors with parathyroid 
hormone (PTH) gene rearrangements (1). Molecular dissection 
showed that in one case the tumor-specific clonal rearrangement 
.separated the PTH gene's 5' fianking region from its coding ex-
ons in a reciprocal recombination event (2). Because the allelic 
rearrangement appeared to be present in every cell of the tumor, 
and thus was apparently present in the tumor's original clonal 
precursor, it was likely to be pathogenetically relevant. One pos-
sibility was that the PTH gene's regulatory elements, which ac-
tively up-regulate PTH transcription in parathyroid tissue, were 
infiuencing the expression of a proto-oncogene that was placed 
in this vicinity by the rearrangement. Such a situation would be 
analogous to the juxtaposition of immunoglobulin sequences 
with the C-MYC or BCL-2 oncogenes in Burkitt's lymphoma or 
follicular lymphoma, respectively (3-5); in both examples the 
tissue-specific enhancer is "tricked" by the DNA rearrangement 
into activating transcription of the misplaced proto-oncogene. 
The DNA of unknown origin that had been rearranged with 
the PTH locus was cloned and found to be normally located on 
chromosome 11; it was initially called Dl 1S287 (2). In situ hy-
bridization more precisely localized D11S287 to band l lq l3 
(2). This localization was intriguing in that 11 q 13 was the estab-
lished location of the known or suspected oncogenes INT-2, 
HST-1, SEA, and BCL-1, as well as the MEN 1 gene, a still un-
identified putative tumor suppressor. The cloned Dl 1S287 se-
quences, however, did not appear to include the INT-2, HST-1, 
SEA, or BCL-l loci, based on restriction map comparisons and 
DNA hybridization data. Because the PTH gene is located on 
the short arm of chromosome 11 (1 lpl5), the simplest cytoge-
netic explanation for the observed molecular rearrangement is a 
pericentromeric inversion; however, direct cytogenetic informa-
tion could not be obtained on the frozen tumor specimen. 
Subsequent study of a panel of tumors at our in.stitution and at 
another revealed two additional and completely independent 
parathyroid adenomas with similar PTH/Dl 1S287 DNA rear-
rangements (6,7). In both cases, the breakpoints within the PTH 
gene are similar to that in the original tumor. Regarding the 
l lq l3 breakpoints, one was approximately 15 kb from that in 
the first tumor (6) (Fig 1), while the other was similar to the orig-
inal breakpoint in this respect (7). 
Next, we showed that a subclone of D11S287 contained a 
transcribed sequence, detectable on blots of parathyroid RNA; 
this expressed sequence was called D11S287E and, later, 
PRADl, for parathyroid adenomatosis-1. The normal size 
PRADl mRNA was overexpressed about 15-fold in all parathy-
roid tumors bearing the clonal PTH/PRAD1 region DNA rear-
rangements (6). This impressive tumor-specific transcriptional 
activation associated with a clonal DNA rearrangement further 
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Fig I—A) Schematic representation of PTH-Dl 1S287 rear-
rangements in two parathyroid adenomas (2,6). The 5' PTH re-
gion (IlpIS, thick lines) was juxtaposed to the Dl IS287 region 
(llql3, thin lines). The breakpoints (X) in the DIIS287 region 
are 15 kh apart. B) Genomic probe B (2) is shown as a darkened 
box, whose open area represents the first e.xon of PRADl. C) 
Restriction maps ofthe inserts of three representative overlap-
ping PRADl cDNA clones, 'kPl-4, XPI-5. and XP2-3. D) De-
duced restriction map ofthe PRADl cDNA. The coding region 
is shown as a crosshatched box. Scale of 1 kilobase is shown as 
arrows. Symbols used for restriction sites are B, BamHI; R, 
EcoRI; H, Hindlll; P, Pstl. (Reprinted hy permission from Na-
ture, Vol 350, pp. 512-5. Copyright © 1991, Macmillan Maga-
zines, Ltd.) 
supported the hypothesis that PRADl was likely a proto-onco-
gene. 
Additional studies have intensified interest in PRADl as a 
candidate oncogene. It has been known for a few years that 15% 
to 20% of human breast cancers and squamous cell cancers of 
the head and neck contain DNA amplification of a part of 1 Iql 3 
that usually includes INT-2, HST-1, and the BCL-l breakpoint 
locus, as reviewed by Lammie et al (8). However, none of these 
loci is invariably present on the amplicon, and none is regularly 
expressed in this subset of tumors. Therefore, it has been as-
sumed that at least one additional oncogene, more central to the 
pathogenesis of these tumors, lies in this vicinity. PRADl is an 
excellent candidate for being such an oncogene, because it was 
recently shown to be consistently present on the 1 lql3 ampli-
con in this subset of breast and squamous cell cancers and, im-
portantiy, was also expressed in the tumors (8). 
PRADl also appears to be a key B-cell lymphoma oncogene. 
Some B-cell tumors contain a translocation involving the im-
munoglobulin heavy chain locus (14q32) with a region on 
l lq l3 . The DNA on l lq l3 adjacent to the breakpoint was 
cloned and named BCLl with the expectation that a new onco-
gene would be found in this DNA and would be deregulated by 
the rearrangement (9). For years, extensive searching of the 
DNA adjacent to the original BCLl breakpoint locus failed to 
reveal a transcribed gene (10,11). Recent data suggest that 
PRADl may be the elusive "BCLl oncogene" because the 
BCLl breakpoint locus is closely linked to PRADl (8,12-14), 
because PRADl appears to be consistently overexpressed in 
centrocytic lymphomas (a subtype characterized by frequent 
BCL-l rearrangements) (13), and because no other CpG island 
lies within the 120 kb between the BCL-l breakpoint and 
PRADl (13,14). Thus, with PRADl being implicated as a puta-
tive oncogene in several tumor types, it was of great interest to 
identify its normal stmcture. 
We screened a human placental cDNA library with Dl 1S287/ 
PRADl genomic probe "B" (Fig 1), already known to contain 
transcribed sequences (6). We obtained overlapping cDNA 
clones that included the full 4.5 kb expected length (Fig 1C and 
ID). PRADl cDNA (EMBL Accession #X59798) encodes a 
295 amino acid protein without close homology to any previ-
ously reported protein, but with a consistent, weaker relation-
ship (Fig 2) to the cyclin A and B families (29% to 34% identity) 
and yeast CLNs or Gl cyclins (19% to 20% identity) (15). Cer-
tain stmctural features raise the question of whether or not 
PRAD 1 might be a human "G1 cyclin" or yeast CLN equivalent, 
controlling the important transition from Gl into S phase of the 
cell cycle. Interestingly, investigators .searching for human G1 
cyclins by rescue of yeast CLN mutants have recently reported 
isolating the PRADl cDNA, now often termed cyclin Dl (16, 
17). Since cyclins A and B, known to function in the S or G2/M 
phases, can also rescue these mutants, these data do not in them-
selves convincingly prove that PRADl/cyclin Dl normally 
functions as a G1 cyclin. In further support ofthis role, however, 
the mouse homologue of PRAD 1 was identified in a search for 
genes that were induced in Gl by colony-stimulating factor 1 
(CSF-1) in macrophages (18). Whatever its function is ulti-
mately determined to be, PRAD I's sequence similarities with 
all known cyclins and the inability to readily assign it to an ex-
isting family indicate that PRAD 1 represents a new cyclin fam-
dy. 
PRADl mRNA is expressed in multiple normal tissues, in-
cluding parathyroid, thyroid, placenta, lymph node, skeletal 
muscle, heart, liver, and breast (15). Northem blots indicate that 
its mRNA is also highly conserved across species from human 
to mouse (15). The amino acid sequence of the mouse homo-
logue of PRADl is 94% identical to the human sequence (18). 
PRADl may also be part of a multigene family in the human 
genome as it is in the mouse; distinct cDNA clones are detect-
able by hybridization at reduced stringency, and we have ob-
served additional bands that hybridize with the PRADl cDNA 
probe on genomic Southem blots washed at decreased strin-
gency. 
PRADl protein was purified after expression in bacteria and 
added to a clam embryo interphase lysate which lacks en-
dogenous cyclins A and B and contains inactive cdc2 kinase 
(19). Subsequentiy, the PRADl protein could be isolated using 
pj3suci (a reagent that avidly binds cdc2-like molecules), imply-
ing but certainly not proving that PRADl had been complexed 
with cdc2 kinase or a related kinase which was directly bound 
by pH "^* '^ (15). Addition of PRADl protein to the same lysate 
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human cyclin A: 
pradl: 
clam cyclin A: 
human cyclin A: 
pradl: 
clsun c y c l i n A: 
MRAILVDWLVEVGEEYKLQNETLHLAVNYIDRFLSSMSVLRGKLQLVGTAAMLLASKFEEIYPPEVAEFVYITDDTYTK 288 
II I * 1**11 II I * * l 11*11*11111 * l ***|||*|** I *||| I I I I * * 
MRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATCMFVASKMKETIPLTAEKLCIYTDNSIRP 134 
I I 1**1 I 11*1 1**11*11II I M i l * ! ! * 11*1*1 I I \' 
MRCILVDWLVEVSEEDKLHRETLFLGVNYIDRFLSKISVLRGKLQLVGAASMFLAAKYEEIYPPDVKEFAYITDDTYTS 273 
KQVLRMEHLVLKVLTFDLAAPTVNQFLTQYFLHQQPANCKVESL. . . AMFLGELSLIDADPYLKYLPSVIAGAA 359 
**| II I * * I **||| I *|* * * I * * * I I I * * 11**1*** 
EELLQMELLLVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVK.FISNPPSMVAAGS 207 
***! II I * * I ***! I * I I I I I *|** ** * I I * ** I I * I I * * 
QQVLRMEHLILKVLTFDVAVPTTNWFCEDFL.KSCDADDK. . . LKSLTMFLTELTLIDMDAYLKYLPSITAAAA 343 
human c y c l i n B: 
pradl: 
cdcl3: 
MRAILIDWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVPKKMLQLVGVTAMFIASKYEEMYPPEIGDFAFVTDNTYTK 279 
I I I * 1***1 * * l *** * ! ! I * * I I 111*1111*111 I I I I I * 
MRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATCMFVASKMKETIPLTAEKLCIYTDNSIRP 134 
I I I * * ! * * ! ! * I 11*1*11111! * l l l * l * * l * ! l l I * ** *|* 
MRGILTDWLIEVHSRFRLLPETLFLAVNIIDRFLSLRVCSLNKLQLVGIAALFIASKYEEVMCPSVQNFVYMADGGYDE 313 
human c y c l i n B: HQIRQMEMKILRALNFGLGRPLPLHFLRR.ASKIGEVDVEQHTL. . .AKYLMELTMLDYDMVHFPPSQIAAGA 348 
pradl: 
Cdcl3: 
I I I P I' I I I I I 
EELLQMELLLVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSMVAAGS 207 
11*111 ** 1*11! I I I I I I I I I I I 
EEILQAERYILRVLEFNLAYPNPMN. . . . FLRRISKADFYDIQTRTVAKYLVEIGLLDHKLLPYPPSQQCAAA 382 
pradl: 
cln3: 
pradl: 
cln3: 
MRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATCMFVASKMKETIPLTA EKLCIYTD 129 
II ** *** I * I I * * I *| I I I * I ****|| ** I * II * 
MRFLIFDFIMYCHTRLNLSTSTLFLTFTILDKYSSRFIIKSYNYQLLSLTALWISSKFWDSKNRMATLKVLQNLC.CNQ 184 
NSIRPEELLQMELLLVNKLKWNLAAMTPHD.FIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSMVAAGS 207 
I 11*1 I I I I I 
YSIK. .QFTTMEMHLFKSLDWSICQSATFDSYIDIFLFQSTSPLSPGWL. . . SAPLEAFIQQKLALLNNAAGTAINKS 258 
Fig 2—Sequence homology in the "cyclin box" region betH'een the predicted PRADl protein and A-type cyclins (human and clam 
cyclin A, 32.2% and33.6% identity, 56.6% and59.2% similarity), B-type cyclins (human cyclin B and Saccharomyces pombe cdc7i, 
29.6% and31.6% identity, 50% and 52% similarity), and one S. cerevisiae Gl cyclin (clni, 19.1% identity, 44.1% similarity). Clam 
cyclin A and S. pombe cdc/i homologies with PRADl are representative of those found in their families; cln3 is better aligned with 
PRADl than is cin/ or 2. I - identical amino acids; * = conservative substitutions. Alignment was made with the assistance of the 
BESTFIT program and conservative amino acids are grouped asfollows; D, E, N, Q; H, K, R; A, G, P. S, T; I, L, M, V; F, W, Y. 
Amino acid numbers are on the right. (Reprinted hy permission from Nature, Vol 350,pp. 512-5. Copyi'ight © 1991, Macmillan Mag-
azines, Ltd.] 
induced phosphorylation of histone HI , a favored substrate for 
cdc2 kinase (15). These preliminary observations support the 
view that PRAD 1 is indeed a new cyclin, both stmcturally and 
functionally, but multiple possibilities regarding its tme physi-
ologic role remain. 
To summarize, therefore, PRADl is a gene that has been 
strongly implicated in the pathogenesis of subsets of parathy-
roid, B-lymphoid, breast, and epidermoid tumors, apparently as 
a direct-acting oncogene activated by clonal rearrangement or 
amplification. PRADl encodes a novel cyclin, whose normal 
function, presumably in cell cycle control, remains unclear at 
this early stage of investigation, but may well be important in 
the crucial Gl-S phase transition that commits a cell to divide. 
Despite PRAD I's location in the genome at 1 Iql 3 and its role in 
sporadic parathyroid neoplasia, it seems unlikely that PRADl is 
the major predisposing gene for MEN 1. First, the 1 Iql3 mark-
ers most closely linked to MEN 1 are centromeric to the BCL-l/ 
PRADl region, probably by a few megabases (20). Second, 
PRAD I's involvement in neoplasia appears to occur in the con-
text of overexpression of the normal gene product due to chro-
mosome rearrangement or amplification, and thus as a direct-
acting oncogene, while the still uncloned MEN 1 gene is likely 
to be a tumor suppressor, participating in neoplasia through its 
loss of function. 
Nonetheless, PRAD 1 could stdl play an important role in the 
parathyroid tumors (and possibly other tumors) in the MEN 1 or 
even MEN 2 syndromes. Such a potential role could be envi-
sioned to involve a somatic DNA change (genetic "hit") that 
contributes to tumor development in a secondary fashion (i.e., 
beyond the required lesion in the MEN 1 gene itself). In this re-
gard, the issue of whether PRADl's location at 1 Iql3 is simply 
a coincidence or whether some 11 q 13 deletional rearrangements 
might activate PRADl in the process of deleting the MEN 1 
gene needs to be explored. 
The precise mechanisms by which deregulated expression of 
PRADl is related to tumor development are unknown. It is even 
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possible that some of its sites of action in neoplasia could be 
qualitatively different from those involved in its normal func-
tion and therefore much study will be required. Such study is 
likely to strengthen our knowledge of the links between the cell 
cycle control apparatus and oncogenic processes in parathyroid 
and other tissues and could well have implications for illuminat-
ing fully the pathogenetic mechanisms in familial endocrine 
neoplasia syndromes. 
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